- Home
- LEXX vs ACHL Comparison
LEXX vs ACHL Comparison
Compare LEXX & ACHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LEXX
- ACHL
- Stock Information
- Founded
- LEXX 2004
- ACHL 2016
- Country
- LEXX Canada
- ACHL United Kingdom
- Employees
- LEXX N/A
- ACHL N/A
- Industry
- LEXX Biotechnology: Pharmaceutical Preparations
- ACHL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LEXX Health Care
- ACHL Health Care
- Exchange
- LEXX Nasdaq
- ACHL Nasdaq
- Market Cap
- LEXX 39.1M
- ACHL 46.0M
- IPO Year
- LEXX N/A
- ACHL 2021
- Fundamental
- Price
- LEXX $1.45
- ACHL $1.38
- Analyst Decision
- LEXX Strong Buy
- ACHL Buy
- Analyst Count
- LEXX 2
- ACHL 2
- Target Price
- LEXX $9.50
- ACHL $4.00
- AVG Volume (30 Days)
- LEXX 110.6K
- ACHL 1.9M
- Earning Date
- LEXX 04-08-2025
- ACHL 04-03-2025
- Dividend Yield
- LEXX N/A
- ACHL N/A
- EPS Growth
- LEXX N/A
- ACHL N/A
- EPS
- LEXX N/A
- ACHL N/A
- Revenue
- LEXX $496,923.00
- ACHL N/A
- Revenue This Year
- LEXX $30.72
- ACHL N/A
- Revenue Next Year
- LEXX $31.85
- ACHL N/A
- P/E Ratio
- LEXX N/A
- ACHL N/A
- Revenue Growth
- LEXX 77.63
- ACHL N/A
- 52 Week Low
- LEXX $1.38
- ACHL $0.63
- 52 Week High
- LEXX $6.85
- ACHL $1.76
- Technical
- Relative Strength Index (RSI)
- LEXX 33.85
- ACHL 72.41
- Support Level
- LEXX $1.38
- ACHL $1.10
- Resistance Level
- LEXX $1.72
- ACHL $1.41
- Average True Range (ATR)
- LEXX 0.12
- ACHL 0.02
- MACD
- LEXX -0.01
- ACHL 0.00
- Stochastic Oscillator
- LEXX 12.85
- ACHL 90.48
About LEXX Lexaria Bioscience Corp.
Lexaria Bioscience Corp's patented drug delivery technology, DehydraTECH improves the way active pharmaceutical ingredients enter the bloodstream by promoting more effective oral delivery. DehydraTECH can increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances with cannabinoids by as much as 27x compared to standard industry formulations, reduce the time of onset from 1-2 hours to minutes, and mask unwanted tastes. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood-brain barrier. The company has four reportable segments: Intellectual Property Licensing which generates maximum revenue, B2B Production, Research and Development, and Corporate. Geographically, it derives revenue from the United States and Canada.
About ACHL Achilles Therapeutics plc
Achilles Therapeutics PLC is a biopharmaceutical company. It is developing AI-powered precision T-cell therapies targeting clonal neoantigens to treat solid tumors. The company has two ongoing trials, the CHIRON trial in patients with non-small-cell lung cancer and the THETIS trial in patients with recurrent or metastatic melanoma.